Literature DB >> 6155118

Apparent insulin resistance due to abnormal enzymatic insulin degradation: a new mechanism for insulin resistance.

A McElduff, C J Eastman, S P Haynes, K M Bowen.   

Abstract

A 16-year-old girl presented with severe, prolonged insulin resistance. Insulin antibodies, initially thought to be responsible for the insulin resistance, were suppressed using monocomponent insulin and immunosuppressive therapy; however insulin resistance persisted. Insulin kinetic studies suggested abnormal metabolism of a bolus injection of 125I insulin and the reappearance in the circulation of radioactive products, demonstrated by chromatography to be of different molecular weight to insulin. These products were of similar molecular weight to material obtained by incubating 125I insulin with protease. Trasylol significantly reduced the patient's insulin requirements and normalised the disappearance of 125I insulin from the circulation. Prolonged treatment with Trasylol resulted in a fall in insulin requirement to non "insulin-resistance" levels. The insulin requirement remained static when Trasylol was ceased. We propose abnormally rapid insulin degradation to be a new mechanism of resistance to insulin therapy.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6155118     DOI: 10.1111/j.1445-5994.1980.tb03421.x

Source DB:  PubMed          Journal:  Aust N Z J Med        ISSN: 0004-8291


  9 in total

1.  'Brittle' diabetes.

Authors:  G Williams; G V Gill; J C Pickup
Journal:  BMJ       Date:  1991-09-21

2.  Inhibition of insulin degradation by hepatoma cells after microinjection of monoclonal antibodies to a specific cytosolic protease.

Authors:  K Shii; R A Roth
Journal:  Proc Natl Acad Sci U S A       Date:  1986-06       Impact factor: 11.205

3.  Lack of pharmacological effect of subcutaneous octreotide in an insulin-dependent diabetic patient: reversal after mixing with aprotinin.

Authors:  M Lunetta; M Di Mauro; R Le Moli
Journal:  J Endocrinol Invest       Date:  1997-06       Impact factor: 4.256

4.  Subcutaneous degradation of insulin.

Authors:  R W Stevenson
Journal:  Diabetologia       Date:  1982-03       Impact factor: 10.122

5.  Insulin degrading enzyme activity and insulin binding of erythrocytes in normal subjects and Type 2 (non-insulin-dependent) diabetic patients.

Authors:  E Standl; H J Kolb
Journal:  Diabetologia       Date:  1984-07       Impact factor: 10.122

6.  Evidence for insulin degradation by muscle and fat tissue in an insulin resistant diabetic patient.

Authors:  G F Maberly; G A Wait; J A Kilpatrick; E G Loten; K R Gain; R D Stewart; C J Eastman
Journal:  Diabetologia       Date:  1982-10       Impact factor: 10.122

7.  Subcutaneous aprotinin causes local hyperaemia. A possible mechanism by which aprotinin improves control in some diabetic patients.

Authors:  G Williams; J C Pickup; S Bowcock; E Cooke; H Keen
Journal:  Diabetologia       Date:  1983-02       Impact factor: 10.122

8.  Management of severely brittle diabetes by continuous subcutaneous and intramuscular insulin infusions: evidence for a defect in subcutaneous insulin absorption.

Authors:  J C Pickup; P D Home; R W Bilous; H Keen; K G Alberti
Journal:  Br Med J (Clin Res Ed)       Date:  1981-01-31

9.  Implantable infusion pump management of insulin resistant diabetes mellitus.

Authors:  H Buchwald; E P Chute; F J Goldenberg; C R Hitchcock; B J Hoogwerf; J J Barbosa; W M Rupp; T D Rohde
Journal:  Ann Surg       Date:  1985-09       Impact factor: 12.969

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.